Smith Hunter C

Smith Hunter C, Chief Financial Officer of an undisclosed company, has demonstrated a pronounced selling bias in recent months, with all 22 of their most recent transactions involving sales of RYTM stock. The transactions, concentrated between February 4 and March 2, 2026, totaled approximately $2.3 million in aggregate value, with individual sales ranging from $10,010 to $358,599. The largest single sale occurred on February 5, 2026, while the most active trading day was February 19, when four separate sales—including the second-largest transaction at $170,754.78—were executed. The only non-sale activity was a single small purchase on March 2 valued at $41,473.20, coded as "M" (likely market acquisition), which stands in stark contrast to the consistent divestment pattern. Historically, Smith Hunter C’s trading activity skews heavily toward selling, with $9.46 million in total lifetime sell value compared to just $572,567.92 in buys across 40 reported transactions. The recent sales of RYTM shares, a biotech or pharmaceutical stock given the ticker’s sector commonality, suggest either portfolio rebalancing or liquidity needs, though no buys in the same period indicate no immediate reinvestment of proceeds. The absence of purchases in recent filings, coupled with the high volume of sales at varying price points, points to a deliberate reduction in exposure to RYTM rather than routine stock-based compensation adjustments. The transactions were executed in rapid succession, with multiple sales often occurring on the same day, reinforcing the systematic nature of the divestment.